Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.

Resistance to β-lactam antibiotics can be mediated by metallo-β-lactamase enzymes (MBLs). An MBL inhibitor could restore the effectiveness of β-lactams. We report on the evaluation of approved thiol-containing drugs as inhibitors of NDM-1, VIM-1, and IMP-7. Drugs were assessed by a novel assay using a purchasable fluorescent substrate and thermal shift. Best compounds were tested in antimicrobial susceptibility assay. Using these orthogonal screening methods, we identified drugs that restored the activity of imipenem.

[1]  K. Li,et al.  HPLC determination of captopril in human plasma and its pharmacokinetic study. , 1996, Biomedical chromatography : BMC.

[2]  T. Raju.  The Nobel Chronicles , 1999, The Lancet.

[3]  T. Raju.  The Nobel Chronicles , 2000, The Lancet.

[4]  Joseph D. Kwasnoski,et al.  High-density miniaturized thermal shift assays as a general strategy for drug discovery. , 2001, Journal of biomolecular screening.

[5]  T. Denneberg,et al.  Pharmacokinetics of oral tiopronin , 2004, European Journal of Clinical Pharmacology.

[6]  Brian J Eastwood,et al.  A Comparison of Assay Performance Measures in Screening Assays: Signal Window, Z' Factor, and Assay Variability Ratio , 2006, Journal of biomolecular screening.

[7]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[8]  C. Bebrone.  Metallo-beta-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. , 2007, Biochemical pharmacology.

[9]  J. Frère,et al.  Structural basis for the broad-spectrum inhibition of metallo-beta-lactamases by thiols. , 2008, Organic & biomolecular chemistry.

[10]  G. Jacoby,et al.  Updated Functional Classification of β-Lactamases , 2009, Antimicrobial Agents and Chemotherapy.

[11]  T. Pruett.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America , 2010 .

[12]  Honggang Zhou,et al.  A structural view of the antibiotic degradation enzyme NDM-1 from a superbug , 2011, Protein & Cell.

[13]  D. Ollis,et al.  The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening. , 2011, Bioorganic & medicinal chemistry letters.

[14]  I. Johnson,et al.  Fluorogenic cephalosporin substrates for β-lactamase TEM-1. , 2011, Analytical biochemistry.

[15]  M. Eberlin,et al.  A Comprehensive Review of the Pharmacodynamics, Pharmacokinetics, and Clinical Effects of the Neutral Endopeptidase Inhibitor Racecadotril , 2012, Front. Pharmacol..

[16]  R. Owens,et al.  Assay Platform for Clinically Relevant Metallo-β-lactamases , 2013, Journal of medicinal chemistry.

[17]  K. Chou,et al.  Metallo-β-lactamases: structural features, antibiotic recognition, inhibition, and inhibitor design. , 2013, Current topics in medicinal chemistry.

[18]  R. Owens,et al.  Chromophore‐Linked Substrate (CLS405): Probing Metallo‐β‐Lactamase Activity and Inhibition , 2013, ChemMedChem.

[19]  Taiyi Wang,et al.  Simplified captopril analogues as NDM-1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[20]  H. Shi,et al.  Engineering the stereochemistry of cephalosporin for specific detection of pathogenic carbapenemase-expressing bacteria. , 2014, Angewandte Chemie.

[21]  N. Strynadka,et al.  Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance , 2014, Nature.